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Two Novel Insulin Receptor Gene Mutations in a Patient with 
Rabson-Mendenhall Syndrome: The First Korean Case Confirmed 
by Biochemical, and Molecular Evidence
Rabson-Mendenhall syndrome (RMS) is a rare syndrome manifested by extreme insulin 
resistance with hyperinsulinemia, acanthosis nigricans, tooth dysplasia and growth 
retardation. Our patient was first noted at the age of 8 months due to pigmentations on 
skin-folded areas. Initial laboratory tests showed normal fasting glucose (69 mg/dL). 
Fasting insulin level was severely elevated, up to 554.6 µIU/mL, and c-peptide level was 
increased, up to 13.81 ng/mL. However, hemoglobin A1c was within normal range (4.8%). 
He is now 11 yr old. His growth development followed the 5-10th percentile and oral 
hypoglycemic agents are being administered. The last laboratory results showed insulin 
364.1 µIU/mL, C-peptide 4.30 ng/mL, and hemoglobin A1c 7.6%. The boy was a 
compound heterozygote for the c.90C > A and c.712G > A mutations of the insulin 
receptor gene, INSR, which are nonsense and missense mutations. In summary, we report 
the first Korean case of RMS, which was confirmed by two novel mutations of the INSR.
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CASE REPORT
Pediatrics
INTRODUCTION
The human insulin receptor is a heterotetramer consisting of 
two extracellular α subunits and two transmembranous and in-
tracellular β subunits. The α subunits mediate insulin binding 
and β subunits have tyrosine kinase activity (1). Insulin binds to 
the α subunit of the receptor and stimulates autophosphoryla-
tion and kinase activity of the β subunit (2). The human insulin 
receptor is coded by the gene INSR, and INSR mutations result 
in insulin resistance (3). 
  There are three types of insulin resistance syndromes. One, 
referred to as type A, includes insulin resistance, acanthosis nigri-
cans, hirsutism, and polycystic ovarian disease in a patient who 
is usually not obese. The second syndrome is leprechaunism, 
which presents with severe hyperglycemia due to insulin resis-
tance, hyperinsulinemia, acanthosis nigricans, hirsutism, thick 
skin with lack of subcutaneous fat, distended abdomen, enlarged 
genitalia in the male, dysmorphic features (elfin-like face, low-
set ears, promitent eyes, thick lips), and growth retardation (4, 5). 
Children afflicted with leprechaunism die within the first 2 yr of 
life (6). The last one is Rabson-Mendenhall Syndrome (RMS), 
which is manifested with severe insulin resistance with hyper-
insulinemia, acanthosis nigricans, tooth and nail dysplasia, 
growth retardation, and pineal hyperplasia. Although patients 
with RMS usually survive beyond 1 year of age, they develop 
constant hyperglycemia followed by diabetic ketoacidosis and 
death. 
  Here, we describe clinical findings in the first Korean RMS 
patient and report two novel mutations of INSR, which were con-
firmed by clinical, biochemical, and molecular findings. 
CASE DESCRIPTION
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8 months due to pigmentations on skin-folded areas, gingival 
hyperplasia, and hirsutism, on 28 December 1999. He was born 
as the first child to healthy non-consanguineous Korean par-
ents at 38 weeks of gestation; birth weight and length were 2,450 g 
(10-25th percentile) and 47 cm (25-50th percentile). Neonatal 
screening tests including 17-hydroxyprogesterone were normal. 
Length and body weight were within the 5-10th percentile at         
8 months old. His face was coarse, with epicanthal folds, and 
low set ears. The hair was curled and bristly. Initial laboratory 
tests showed normal fasting glucose, 69 mg/dL (reference range; 
RR, 60-100 mg/dL). Fasting insulin level was severely elevated, 
up to 554.6 µIU/mL (RR, 7-24 µIU/mL), and c-peptide level was 
increased, up to 13.81 ng/mL (RR, 0.4-2.2 ng/mL). However, the 
percent of glycosylated hemoglobin (HbA1c) was within normal 
range; 4.8% (RR, 4.5%-6.5%). AST and ALT were slightly elevated, 
to 51 U/L (RR, 15-55 U/L) and 49 U/L (RR, 5-45 U/L). We per-
formed an intravenous glucose tolerance test to rule out insulin 
resistance syndromes. Fasting glucose and insulin level were 
normal; 57 mg/dL, 3.7 µIU/mL. After IV administration of glu-
cose (0.3 g/kg), rapid increase of glucose level up to 204 mg/dL 
was observed after 2 min, and insulin level was extremely ele-
vated up to 2,508 µIU/mL. Maximal elevation of insulin level 
was 3,300 µIU/mL after 4 min, which suggested extreme hyper-
insulinemia to glucose load. However, hyperglycemia was not 
demonstrated usually. Therefore, we did not administer any 
type of hypoglycemic agents. Results of skin biopsy of the pig-
mented neck revealed acanthosis nigricans. 
  At 13 months old, his fasting glucose was checked, up to 128 
mg/dL with glucosuria (+++); therefore, a low-sugar diet and 
oral hypoglycemic agent (metformin 250 mg/day) therapy were 
started. At the age of 18 months, he started growth hormone ther-
apy due to poor height gain and low IGF-1 level of 14.3 ng/mL 
(RR, 31-160 ng/mL). However, we stopped growth hormone 
therapy after 3 months, due to minimal effect and hyperglyce-
mia. At the age of nine years old, he was admitted to our hospi-
tal due to poor glycemic control (HbA1c 11.0%), thereafter,       
additional oral hypoglycemic agents (metformin 500 mg bid, 
glimepiride 2 mg bid, and voglibose 0.2 mg tid) have been ad-
ministered until now, with HbA1c less than 8%. 
  He is now 11 yr old. Acanthosis nigricans lesions have shown 
improvement, and dark skin color has brightened. Protrusion 
of lips, teeth crowding, macrodontia, and abnormal dentition 
(Fig. 1) are observed. Severe growth retardation has not been 
demonstrated; weight of 5-10th percentile and height of 10-25th 
percentile. Body mass index is 15.7 kg/m
2. Developmental state 
and neurologic examination are normal. 
  Recent laboratory tests performed at the age of 10 yr still showed 
increased insulin resistance and subsequent hyperglycemia; 
insulin 364.1 µIU/mL (RR, 7-24 µIU/mL), C-peptide, 4.30 ng/mL 
(RR, 0.4-2.2 ng/mL), Hb A1c 7.6%. Hyperandrogenism was not 
demonstrated; testosterone, 0.08 ng/mL (RR, 0.03-0.1 ng/mL). 
His dental age was advanced, compared with chronologic age. 
Bone ages fit with his chronological age. He has not experienced 
diabetic ketotic acidosis, and has had no complications until now.
  For identification of the underlying genetic defect, we per-
formed molecular genetic testing for the INSR gene. After in-
formed consent had been obtained, blood samples were col-
lected from the patient. Genomic DNA was isolated from periph-
eral blood leukocytes using the Wizard Genomic DNA Purifica-
tion Kit (Promega, Madison, WI, USA). Primers designed by the 
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Fig. 1. Dentition photographs were taken at the age of 10 yr old. Note the abnormal 
dentition, which includes proclined upper and lower incisors (A), and crowding on 
lower teeth, macrodontia (B).
Fig. 2. Direct sequencing of the INSR gene in our patient. Compound heterozygous for two mutations were identified: c.90C>A (p.Tyr30X) in exon 1 and c.712G>A (p.Glu238Lys) 
in exon 3 (arrows).
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authors were used for amplification of all coding exons and their 
flanking intronic sequences of the INSR gene by polymerase 
chain reaction using a thermal cycler (Model 9700; Applied Bio-
systems, Foster City, CA, USA). Direct sequencing was performed 
using the same primer sets and the BigDye Terminator Cycle 
Sequencing Ready Reaction kit (Applied Biosystems, Rotkreuz, 
Switzerland) on the ABI Prism 3130xl genetic analyzer (Applied 
Biosystems, Foster City, CA, USA). In result, two novel variations 
were identified (Fig. 2). One is a C to A transversion at nucleotide 
position 90 (c.90C > A) in exon 1, replacing tyrosine to a prema-
ture stop codon at codon 30 (p.Tyr30X). The other is a G to A 
transition at the nucleotide position 712 (c.712G > A) in exon 3, 
replacing glutamic acid with lysine at codon 238 (p.Glu238Lys). 
DISCUSSION
Leprechaunism and RMS are both autosomal recessive diseas-
es with abnormal alleles for insulin receptors. Mutations in the 
INSR cause a spectrum of inherited insulin-resistance syndromes 
ranging from leprechaunism, in which afflicted children die in 
infancy, to type A insulin resistance, usually evident after puberty. 
RMS has an intermediate phenotype. Cells from most patients 
with leprechaunism show absent or severely impaired insulin 
binding to insulin receptor, whereas cells from patients with 
RMS retain some insulin binding capacity (7). Therefore, the 
severity of the phenotype seems to be determined by the degree 
of insulin resistance and that residual insulin binding capacity 
correlates with survival (8). 
  In this patient, several pieces of evidence, including hyperin-
sulinemia with insulin resistance, acanthosis nigricans, hirsut-
ism, abnormal dental findings, and peculiar morphology sug-
gested leuprechaunism or RMS. Our patient had showed rela-
tively mild phenotype and lived longer than 2 yr, therefore he 
was diagnosed as RMS. 
  In most cases, nonsense mutations cause leprechaunism phe-
notype by reduction of insulin binding activity (8). Patients with 
leprechaunism had α subunit mutations or homozygosity in β 
subunit mutations, which tend to predict a more severe clinical 
course (9). Most patients with type A syndrome had heterozy-
gous mutations in the β subunit, which affect kinase activity 
and result in a mild decrease in insulin binding capacity (8, 10). 
Reported mutations of RMS, located within the α subunit of the 
INSR gene, were homozygous mutations, including C284Y/
C284Y (11), S323L/S323L (12), and heterozygous mutations   
including N15K/R1000X(β subunit) (13), C159F/R229C (7), and 
H209R/359S (14). Reported mutations of RMS, located within 
the β subunit of the INSR gene, were heterozygous mutations, 
including I1131T (10), R1131W (10), P970T (8), I1115T (10), 
I1116T (8), R1174W (8), and R1000X/N15K (α subunit) (13). 
  Previously, we cultured fibroblast cells from skin in this case 
and suggested the possible mechanism of insulin resistance at 
the molecular level; however, at that time, we failed to identify 
the mutation in the patient (6). Now, we have determined that 
this patient had one novel nonsense mutation (p.Y30X) and an-
other novel missense mutation (p.E238K) within the α subunit 
of the INSR. Tyrosine 30 is in the extracellular L1 domain; how-
ever, the exact function of this region is unknown. Glutamic acid 
238 is in the extracellular Furin-like Cystein-rich domain of α sub-
units. Some of these cysteines are thought to participate in main-
tenance of the structure of the insulin-binding site through estab-
lishment of disulfide bonds between α subunits (15). However, 
the cystein-rich domain does not appear to contain direct insu-
lin/insulin receptor contact sites (16). Characterization of the 
naturally occurring point mutations P193L (17), H209R (18), 
and L233P (19) also suggests that this domain is important for 
insulin receptor processing and transport to the cell surface. In 
particular, close proximity to our p.E238K mutation, a missense 
mutation at amino acid position 233 in exon 3 (p.L233P), has 
previously been shown to completely block processing and trans-
port of insulin receptor to the cell surface (19, 20), which would 
not alter qualitative insulin binding activities in vitro (7). 
  As described above, it is reported that only missense muta-
tions were within α subunit of the INSR gene in RMS, and non-
sense mutations in α subunits have only been found in lepre-
chaunism. In conclusion, we report a case of two novel muta-
tions in α subunit of the INSR; which is the first case of RMS 
where a nonsense mutation is located within the α subunit of 
the INSR.
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